CO2024003915A2 - Nuevo anticuerpo monoclonal nav1.7 - Google Patents

Nuevo anticuerpo monoclonal nav1.7

Info

Publication number
CO2024003915A2
CO2024003915A2 CONC2024/0003915A CO2024003915A CO2024003915A2 CO 2024003915 A2 CO2024003915 A2 CO 2024003915A2 CO 2024003915 A CO2024003915 A CO 2024003915A CO 2024003915 A2 CO2024003915 A2 CO 2024003915A2
Authority
CO
Colombia
Prior art keywords
monoclonal antibody
new monoclonal
chain variable
variable region
new
Prior art date
Application number
CONC2024/0003915A
Other languages
English (en)
Spanish (es)
Inventor
Mai YOSHIKAWA
Junji Onoda
Daiki Nakamori
Tatsuya Takahashi
Erika KASAI
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of CO2024003915A2 publication Critical patent/CO2024003915A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CONC2024/0003915A 2021-11-01 2024-03-27 Nuevo anticuerpo monoclonal nav1.7 CO2024003915A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021178982 2021-11-01
JP2022005967 2022-01-18
PCT/JP2022/040580 WO2023074888A1 (ja) 2021-11-01 2022-10-31 新規なNav1.7モノクローナル抗体

Publications (1)

Publication Number Publication Date
CO2024003915A2 true CO2024003915A2 (es) 2024-04-18

Family

ID=86159498

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0003915A CO2024003915A2 (es) 2021-11-01 2024-03-27 Nuevo anticuerpo monoclonal nav1.7

Country Status (12)

Country Link
US (1) US20250163145A1 (https=)
EP (1) EP4428239A4 (https=)
JP (1) JP7457880B2 (https=)
KR (1) KR102753603B1 (https=)
AU (1) AU2022377536B2 (https=)
CA (1) CA3236404A1 (https=)
CO (1) CO2024003915A2 (https=)
IL (1) IL311683B2 (https=)
MX (1) MX2024004393A (https=)
MY (1) MY206945A (https=)
TW (1) TWI867354B (https=)
WO (1) WO2023074888A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024225446A1 (ja) * 2023-04-28 2024-10-31 塩野義製薬株式会社 新規なNav1.7モノクローナル抗体を含む医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214973B1 (en) 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
MX2015010749A (es) 2013-03-14 2015-11-30 Regeneron Pharma Anticuerpos humanos para nav1.7.
JP2016529909A (ja) * 2013-09-05 2016-09-29 デューク ユニバーシティ Nav1.7抗体及び前記抗体を使用する方法
GB2517953A (en) 2013-09-05 2015-03-11 Argen X Bv Antibodies to complex targets
JPWO2019230856A1 (ja) * 2018-05-31 2021-06-24 塩野義製薬株式会社 Nav1.7モノクローナル抗体
US20240002497A1 (en) 2020-11-19 2024-01-04 Merck Sharp & Dohme Llc Nav1.7 binders
WO2024225446A1 (ja) * 2023-04-28 2024-10-31 塩野義製薬株式会社 新規なNav1.7モノクローナル抗体を含む医薬組成物

Also Published As

Publication number Publication date
KR102753603B1 (ko) 2025-01-13
CA3236404A1 (en) 2023-05-04
JPWO2023074888A1 (https=) 2023-05-04
WO2023074888A1 (ja) 2023-05-04
TWI867354B (zh) 2024-12-21
EP4428239A4 (en) 2025-10-29
IL311683B2 (en) 2026-04-01
JP7457880B2 (ja) 2024-03-28
IL311683B1 (en) 2025-12-01
KR20240099394A (ko) 2024-06-28
MY206945A (en) 2025-01-21
TW202325739A (zh) 2023-07-01
AU2022377536A1 (en) 2024-04-11
EP4428239A1 (en) 2024-09-11
AU2022377536B2 (en) 2024-10-24
MX2024004393A (es) 2024-04-30
US20250163145A1 (en) 2025-05-22
IL311683A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
CL2016000324A1 (es) Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1.
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CL2025000404A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
CL2024003681A1 (es) Conjugado de anticuerpo anti-b7h3-fármaco y uso del mismo
AU2021298632A8 (en) Anti-CD70 antibody and application thereof
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
CL2015001895A1 (es) Anticuerpos que se unen al tl1a y sus usos
CO2022004743A2 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
MX2024009976A (es) Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso.
PE20190208A1 (es) Anticuerpos que reconocen tau
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MX2022001133A (es) Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
DOP2023000214A (es) Conjugados de anticuerpo anti-nectina-4 y exatecano
CO2024003915A2 (es) Nuevo anticuerpo monoclonal nav1.7
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
AR103840A1 (es) ANTICUERPOS IgG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS
PE20211296A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
MX2020007401A (es) Novedosa combinacion y uso de anticuerpos.
MX394735B (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
PE20230374A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
AR112563A1 (es) Anticuerpos monoclonales anti-sortilina útiles en la corrección de un nivel deficiente de progranulina (pgrn)
MX2022012913A (es) Anticuerpo anti-ox40 y usos del mismo.
CL2021000585A1 (es) Métodos para tratar la pancreatitis